Touchlight, based in London, UK, is the world’s leading GMP manufacturer of synthetic DNA. The company is pioneering enzymatic DNA production to enable the revolution in genetic medicines, including DNA and mRNA vaccines and cell and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as dbDNA™ (doggybone DNA).
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to produce genes with a size and complexity that is impossible with current technologies.
Touchlight is enabling companies across the genetic medicine industry with multiple client programmes in the clinic across modalities. The company provides contract development and manufacturing capabilities to produce dbDNA as a critical starting material and active pharmaceutical ingredient for use in advanced therapies.
